These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 29860286)

  • 1. Are Alternative Strategies Required to Accelerate the Global Elimination of Lymphatic Filariasis? Insights From Mathematical Models.
    Stolk WA; Prada JM; Smith ME; Kontoroupis P; de Vos AS; Touloupou P; Irvine MA; Brown P; Subramanian S; Kloek M; Michael E; Hollingsworth TD; de Vlas SJ
    Clin Infect Dis; 2018 Jun; 66(suppl_4):S260-S266. PubMed ID: 29860286
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Triple-drug therapy with ivermectin, diethylcarbamazine and albendazole for the acceleration of lymphatic filariasis elimination in Kenya: Programmatic implementation and results of the first impact assessment.
    Njenga SM; Kanyi H; Okoyo C; Githinji E; Mwatele C; Matendechero SH; Omondi WP; Gitahi PN; Owaga C; Onsongo JK; Gass K
    PLoS Negl Trop Dis; 2024 Jul; 18(7):e0011942. PubMed ID: 38976718
    [TBL] [Abstract][Full Text] [Related]  

  • 3. How Does the Proportion of Never Treatment Influence the Success of Mass Drug Administration Programs for the Elimination of Lymphatic Filariasis?
    Kura K; Stolk WA; Basáñez MG; Collyer BS; de Vlas SJ; Diggle PJ; Gass K; Graham M; Hollingsworth TD; King JD; Krentel A; Anderson RM; Coffeng LE
    Clin Infect Dis; 2024 Apr; 78(Supplement_2):S93-S100. PubMed ID: 38662701
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mathematical modelling of lymphatic filariasis elimination programmes in India: required duration of mass drug administration and post-treatment level of infection indicators.
    Jambulingam P; Subramanian S; de Vlas SJ; Vinubala C; Stolk WA
    Parasit Vectors; 2016 Sep; 9(1):501. PubMed ID: 27624157
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Community-based trial of annual versus biannual single-dose ivermectin plus albendazole against Wuchereria bancrofti infection in human and mosquito populations: study protocol for a cluster randomised controlled trial.
    de Souza DK; Ahorlu CS; Adu-Amankwah S; Otchere J; Mensah SK; Larbi IA; Mensah GE; Biritwum NK; Boakye DA
    Trials; 2017 Oct; 18(1):448. PubMed ID: 28969715
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive Value of Microfilariae-Based Stop-MDA Thresholds After Triple Drug Therapy With IDA Against Lymphatic Filariasis in Treatment-Naive Indian Settings.
    James A; Coffeng LE; Blok DJ; King JD; de Vlas SJ; Stolk WA
    Clin Infect Dis; 2024 Apr; 78(Supplement_2):S131-S137. PubMed ID: 38662696
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of mass drug administration with a single-dose triple-drug regimen of albendazole + diethylcarbamazine + ivermectin for lymphatic filariasis in Papua New Guinea: An open-label, cluster-randomised trial.
    Tavul L; Laman M; Howard C; Kotty B; Samuel A; Bjerum C; O'Brian K; Kumai S; Amuga M; Lorry L; Kerry Z; Kualawi M; Karl S; Makita L; John LN; Bieb S; Wangi J; Weil GJ; Goss CW; Tisch DJ; Pomat W; King CL; Robinson LJ
    PLoS Negl Trop Dis; 2022 Feb; 16(2):e0010096. PubMed ID: 35139070
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An open label, block randomized, community study of the safety and efficacy of co-administered ivermectin, diethylcarbamazine plus albendazole vs. diethylcarbamazine plus albendazole for lymphatic filariasis in India.
    Jambulingam P; Kuttiatt VS; Krishnamoorthy K; Subramanian S; Srividya A; Raju HKK; Rahi M; Somani RK; Suryaprakash MK; Dwivedi GP; Weil GJ
    PLoS Negl Trop Dis; 2021 Feb; 15(2):e0009069. PubMed ID: 33591979
    [TBL] [Abstract][Full Text] [Related]  

  • 9. How Thailand eliminated lymphatic filariasis as a public health problem.
    Rojanapanus S; Toothong T; Boondej P; Thammapalo S; Khuanyoung N; Santabutr W; Prempree P; Gopinath D; Ramaiah KD
    Infect Dis Poverty; 2019 May; 8(1):38. PubMed ID: 31130143
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reaching endpoints for lymphatic filariasis elimination- results from mass drug administration and nocturnal blood surveys, South Gujarat, India.
    Modi A; Gamit S; Jesalpura BS; Kurien G; Kosambiya JK
    PLoS Negl Trop Dis; 2017 Apr; 11(4):e0005476. PubMed ID: 28369129
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of co-administered diethylcarbamazine, albendazole and ivermectin during mass drug administration for lymphatic filariasis in Haiti: Results from a two-armed, open-label, cluster-randomized, community study.
    Dubray CL; Sircar AD; Beau de Rochars VM; Bogus J; Direny AN; Ernest JR; Fayette CR; Goss CW; Hast M; O'Brian K; Pavilus GE; Sabin DF; Wiegand RE; Weil GJ; Lemoine JF
    PLoS Negl Trop Dis; 2020 Jun; 14(6):e0008298. PubMed ID: 32511226
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospects for elimination of bancroftian filariasis by mass drug treatment in Pondicherry, India: a simulation study.
    Stolk WA; Swaminathan S; van Oortmarssen GJ; Das PK; Habbema JD
    J Infect Dis; 2003 Nov; 188(9):1371-81. PubMed ID: 14593597
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of ivermectin and albendazole combination in suppressing transmission of lymphatic filariasis following mass administration in Tanzania: a prospective cohort study.
    Fimbo AM; Mnkugwe RH; Mlugu EM; Kunambi PP; Malishee A; Minzi OMS; Kamuhabwa AAR; Aklillu E
    Infect Dis Poverty; 2024 Jun; 13(1):44. PubMed ID: 38867265
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lymphatic filariasis elimination efforts in Rufiji, southeastern Tanzania: decline in circulating filarial antigen prevalence in young school children after twelve rounds of mass drug administration and utilization of long-lasting insecticide-treated nets.
    Jones C; Ngasalla B; Derua YA; Tarimo D; Malecela MN
    Int J Infect Dis; 2017 Aug; 61():38-43. PubMed ID: 28527817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lymphatic filariasis control in Tanzania: effect of six rounds of mass drug administration with ivermectin and albendazole on infection and transmission.
    Simonsen PE; Derua YA; Kisinza WN; Magesa SM; Malecela MN; Pedersen EM
    BMC Infect Dis; 2013 Jul; 13():335. PubMed ID: 23870103
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of a triple-drug regimen for global elimination of lymphatic filariasis: a modelling study.
    Irvine MA; Stolk WA; Smith ME; Subramanian S; Singh BK; Weil GJ; Michael E; Hollingsworth TD
    Lancet Infect Dis; 2017 Apr; 17(4):451-458. PubMed ID: 28012943
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of annual mass administration of diethylcarbamazine and albendazole on bancroftian filariasis in five villages in south India.
    Ramaiah KD; Vanamail P; Yuvaraj J; Das PK
    Trans R Soc Trop Med Hyg; 2011 Aug; 105(8):431-7. PubMed ID: 21601901
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An open label, randomized clinical trial to compare the tolerability and efficacy of ivermectin plus diethylcarbamazine and albendazole vs. diethylcarbamazine plus albendazole for treatment of brugian filariasis in Indonesia.
    Supali T; Djuardi Y; Christian M; Iskandar E; Alfian R; Maylasari R; Destani Y; Lomiga A; Minggu D; Lew D; Bogus J; Weil GJ; Fischer PU
    PLoS Negl Trop Dis; 2021 Mar; 15(3):e0009294. PubMed ID: 33780481
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mass drug administration of ivermectin, diethylcarbamazine, plus albendazole compared with diethylcarbamazine plus albendazole for reduction of lymphatic filariasis endemicity in Papua New Guinea: a cluster-randomised trial.
    Laman M; Tavul L; Karl S; Kotty B; Kerry Z; Kumai S; Samuel A; Lorry L; Timinao L; Howard SC; Makita L; John L; Bieb S; Wangi J; Albert JM; Payne M; Weil GJ; Tisch DJ; Bjerum CM; Robinson LJ; King CL
    Lancet Infect Dis; 2022 Aug; 22(8):1200-1209. PubMed ID: 35533701
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Toward the elimination of lymphatic filariasis by 2020: treatment update and impact assessment for the endgame.
    Rebollo MP; Bockarie MJ
    Expert Rev Anti Infect Ther; 2013 Jul; 11(7):723-31. PubMed ID: 23879610
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.